CDC Workforce Cuts Threaten Emergency Response Capacity, Survey Finds
A survey of over 600 CDC employees conducted between February and April 2026 found that 99% believe the Trump administration's changes have reduced the agency's capacity to respond to public health emergencies. The cuts come as an Ebola outbreak grows in Central Africa and measles cases spread domestically, with key leadership positions remaining vacant. The findings raise concerns about the CDC's ability to deploy personnel and communicate effectively during health crises.
Researchers at Michigan State University surveyed current and former CDC employees to assess the impact of workforce reductions and leadership changes at the Centers for Disease Control and Prevention since January 2025. The survey of 433 current and 191 former employees found overwhelming concern about the agency's diminished capacity to prevent, detect, and control disease. The CDC has experienced mass firings, communication freezes, and political interference, with critical leadership positions—including director, principal deputy director, chief of staff, and chief medical officer—remaining unfilled nearly a year after the firing of Director Susan Monarez. The timing is particularly concerning given concurrent public health challenges: an Ebola outbreak in Central Africa and measles outbreaks in the United States. The survey respondents noted that communication about ongoing disease outbreaks has been confusing and sparse, and expressed concern that the agency may lack sufficient personnel to mount deployments comparable to the 3,000+ sent during the 2014-2016 Ebola outbreak.
What's missing
The article does not specify the exact number or percentage of CDC workforce reductions since January 2025, nor does it detail the specific budget cuts implemented. Additionally, the article does not include responses or statements from the Trump administration or HHS leadership defending or explaining the rationale for the changes.
What different sources said
- The ConversationCenter
How cuts to CDC are dismantling its capacity to protect Americans’ health
Related
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.
AI's Growing Role in Clinical Trials Depends on Skilled Implementation
Artificial intelligence is being integrated across clinical trials for drug discovery, patient selection, protocol design, and data management. The technology shows particular promise for rare disease research through AI-powered artificial twins that could replace traditional placebo controls. However, experts emphasize that AI tools are only effective when properly implemented by trained personnel who prioritize patient outcomes over technological advancement.
US Suicide Deaths Fall Nationally, but Several States See Sharp Increases
National suicide deaths fell 3% between 2023-2024, but New Hampshire experienced a 12% increase, with Iowa, Connecticut, and South Carolina also seeing double-digit or near double-digit rises. The report from Trust for America's Health notes that rural areas tend to have higher suicide rates, though the specific causes of state-level variations remain unclear. Regional disparities persist, with the Midwest showing the highest suicide rates and the Northeast the lowest, though all regions have increased substantially since 2004.